SaiBeiXin (Pazopanib Tablets) – Anti Tumors | HongKong DengYue Medicine

Pazopanib Tablets Application Scope

• Advanced renal cell carcinoma (RCC)

• Advanced soft tissue sarcoma (STS) who have received prior chemotherapy

• Note: Efficacy for adipocytic STS or gastrointestinal stromal tumors has not been demonstrated

Pazopanib Tablets Characteristics

• Ingredients: Active ingredient: Pazopanib hydrochloride

• Properties: Pazopanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), c-KIT, and fibroblast growth factor receptors (FGFR)

• Packaging Specification: 200 mg and 400 mg film-coated tablets

• Storage: Store below 30°C in the original container

• Expiry Date: Refer to the packaging for the specific expiry date

• Executive Standard: Complies with applicable national and international standards

• Approval Number: NDA 022465

• Date of Revision: Refer to the packaging for the specific date

• Manufacturer: Novartis Pharmaceuticals Corporation

 

 

Guidelines for the Use of Pazopanib Tablets

• Dosage and Administration: Take 800 mg (four 200 mg tablets) orally once daily without food (at least 1 hour before or 2 hours after a meal) until disease progression or unacceptable toxicity

  • Recommended Dose: 800 mg orally once daily

  • Administration: Swallow tablets whole; do not crush or chew

  • Missed Dose:​ If a dose is missed, take it as soon as possible unless it is within 12 hours of the next scheduled dose; do not take two doses at the same time

• Adverse Reactions:

  • Common Adverse Reactions: Diarrhea, hypertension, nausea, fatigue, hair color changes, rash, and liver enzyme abnormalities

  • Serious Adverse Reactions: Severe hepatotoxicity, QT interval prolongation, cardiac dysfunction, gastrointestinal perforation, and hemorrhage

    ​

• Contraindications: Hypersensitivity to pazopanib or any component of the formulation

• Precautions:

  • Monitor liver function regularly during treatment

  • Use with caution in patients with a history of QT interval prolongation or cardiac arrhythmias

  • Avoid concurrent use with strong CYP3A4 inhibitors or inducers

Pazopanib Tablets Interactions

• Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase pazopanib serum levels

• Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease pazopanib serum levels

• Pazopanib is a substrate of P-glycoprotein (P-gp); co-administration with P-gp inhibitors may affect its pharmacokinetics

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.